Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Rodbard · SciRah

Researcher profile · Semantic Scholar

H. Rodbard

Share profile

H. Rodbard — researcher profile on SciRah

h-index: 48
Works: 168
Citations: 11K

Most-cited papers

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
H. Rodbard, J. Rosenstock, L. Canani, C. Deerochanawong +6 more
2019Diabetes Care401 citations Open access
Semantic Scholar
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
H. Rodbard, I. Lingvay, J. Reed, R. E. de la Rosa +6 more
2018Journal of Clinical Endocrinology and Metabolism366 citations Open access
Semantic Scholar
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
T. Danne, S. Garg, A. Peters, J. Buse +26 more
2019Diabetes Care321 citations Open access
Semantic Scholar
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
S. Gough, B. Bode, V. Woo, H. Rodbard +4 more
2014The Lancet Diabetes and Endocrinology309 citations
Semantic Scholar
Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
J. Buse, T. Vilsbøll, J. Thurman, T. Blevins +3 more
2014Diabetes Care254 citations Open access
Semantic Scholar
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
P. Dandona, C. Mathieu, M. Phillip, L. Hansen +163 more
2017The Lancet Diabetes and Endocrinology237 citations Open access
Semantic Scholar
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Liana K. Billings, A. Doshi, D. Gouet, A. Oviedo +5 more
2018Diabetes Care180 citations Open access
Semantic Scholar
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
J. Cornel, G. Bakris, Susanna R. Stevens, M. Alvarsson +13 more
2016Diabetes Care170 citations
Semantic Scholar
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)
C. Mathieu, H. Rodbard, B. Cariou, Y. Handelsman +4 more
2014Diabetes, obesity and metabolism160 citations Open access
Semantic Scholar
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
J. Rosenstock, Juan P. Frías, H. Rodbard, S. Tofé +4 more
2023Journal of the American Medical Association (JAMA)148 citations Open access
Semantic Scholar
One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial
S. Gough, B. Bode, V. Woo, H. Rodbard +4 more
2015Diabetes, obesity and metabolism124 citations Open access
Semantic Scholar
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
E. Michos, G. Bakris, H. Rodbard, Katherine R. Tuttle
2023American Journal of Preventive Cardiology111 citations Open access
Semantic Scholar
Short Report: Treatment Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial
H. Rodbard, B. Cariou, B. Zinman, Y. Handelsman +4 more
2013104 citations
Semantic Scholar
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
H. Rodbard, B. Bode, S. Harris, L. Rose +3 more
2016Diabetic Medicine103 citations Open access
Semantic Scholar
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
A. Ahmann, H. Rodbard, J. Rosenstock, J. Lahtela +4 more
2015Diabetes, obesity and metabolism101 citations Open access
Semantic Scholar
Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial.
H. Rodbard, Virginia E. Visco, H. Andersen, L. C. Hiort +1 more
2014The Lancet Diabetes and Endocrinology89 citations
Semantic Scholar
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes
H. Rodbard, A. Peters, A. Slee, A. Cao +2 more
2016Diabetes Care86 citations Open access
Semantic Scholar
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
J. Buse, H. Rodbard, Carlos Trescolí Serrano, Junxiang Luo +5 more
2015Diabetes Care83 citations Open access
Semantic Scholar
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
R. Josse, S. Majumdar, Yinggan Zheng, A. Adler +10 more
2017Diabetes, obesity and metabolism64 citations
Semantic Scholar
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
H. Rodbard, J. Seufert, N. Aggarwal, A. Cao +3 more
2016Diabetes, obesity and metabolism57 citations Open access
Semantic Scholar
Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
N. Pagidipati, Yinggan Zheng, J. Green, D. McGuire +8 more
2019American Heart Journal55 citations
Semantic Scholar
Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
H. Rodbard, S. Gough, W. Lane, L. Korsholm +2 more
2014Endocrine Practice54 citations
Semantic Scholar
Reduced Risk of Confirmed Hypoglycemia (Plasma Glucose <2.3 mmol/L) with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes: A Meta-analysis of 5 Randomized Trials
A. Garber, T. Hobbs, S. Rasmussen, Jina Hahn +1 more
201349 citations
Semantic Scholar
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials
Hiren Patel, K. Khunti, H. Rodbard, H. Bajaj +3 more
2023Diabetes, obesity and metabolism45 citations Open access
Semantic Scholar
A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes
J. Tibaldi, M. Hadley-Brown, A. Liebl, Steffen Haldrup +3 more
2019Diabetes, obesity and metabolism44 citations Open access
Semantic Scholar
Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)
H. Rodbard, D. Tripathy, Maricela Vidrio Velázquez, M. Demissie +2 more
2017Diabetes, obesity and metabolism44 citations Open access
Semantic Scholar
Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
H. Rodbard, B. Cariou, T. Pieber, Lars Endahl +2 more
2016Diabetes, obesity and metabolism44 citations Open access
Semantic Scholar
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
L. Perreault, H. Rodbard, V. Valentine, Eric L. Johnson
2019Advances in Therapy42 citations Open access
Semantic Scholar
Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care.
H. Rodbard, Tanya Dougherty, Patty Taddei-Allen
2020American Journal of Managed Care41 citations
Semantic Scholar
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
H. Rodbard, J. Buse, V. Woo, T. Vilsbøll +3 more
2015Diabetes, obesity and metabolism40 citations Open access
Semantic Scholar
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
A. Peters, D. McGuire, T. Danne, J. Kushner +7 more
2020Diabetes Care38 citations Open access
Semantic Scholar
IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test
J. Holst, J. Buse, H. Rodbard, S. Linjawi +4 more
2015Journal of Diabetes Science and Technology34 citations Open access
Semantic Scholar
Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare).
B. Bode, L. Chaykin, A. Sussman, M. Warren +3 more
2014Endocrine Practice31 citations
Semantic Scholar
The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
H. Rodbard
2018Diabetes Technology & Therapeutics28 citations Open access
Semantic Scholar
Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)
R. Conway, H. Rodbard, Ildiko Lingvay, J. Reed +7 more
201628 citations
Semantic Scholar
Biosynthetic Human Insulin and Insulin Analogs.
H. Rodbard, D. Rodbard
2020American Journal of Therapeutics26 citations
Semantic Scholar
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
T. Danne, J. Pettus, A. Giaccari, B. Cariou +8 more
2019Diabetes Technology & Therapeutics26 citations Open access
Semantic Scholar
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, K. Barnard-Kelly, T. Battelino, A. Ceriello +39 more
2024Cardiovascular Diabetology22 citations Open access
Semantic Scholar
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Jaime P. Almandoz, L. Anderson, K. Barnard-Kelly +46 more
2025Cardiovascular Diabetology21 citations Open access
Semantic Scholar
Humanistic and Economic Burden of Patients with Cardiorenal Metabolic Conditions: A Systematic Review
K. Ferdinand, Keith C. Norris, H. Rodbard, Jennifer M. Trujillo
2023Diabetes Therapy19 citations Open access
Semantic Scholar
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
M. Blüher, A. Ceriello, Melanie J. Davies, H. Rodbard +4 more
2022Endocrinology, Diabetes & Metabolism17 citations Open access
Semantic Scholar
GREATER COMBINED REDUCTIONS IN HBA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VS COMPARATORS IN TYPE 2 DIABETES.
H. Rodbard, S. Bellary, I. Hramiak, Y. Seino +5 more
2019Endocrine Practice17 citations Open access
Semantic Scholar
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
O. Schnell, T. Battelino, R. Bergenstal, M. Blüher +26 more
2022Cardiovascular Diabetology15 citations Open access
Semantic Scholar
1.1 IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial (65-OR)
J. Buse, S. Gough, V. Woo, H. Rodbard +4 more
2013Nederlands Tijdschrift voor Diabetologie15 citations
Semantic Scholar
Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2
H. Rodbard, A. Giaccari, Rosemarie Lajara, J. Stewart +4 more
2020Diabetes, obesity and metabolism14 citations
Semantic Scholar
Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop
K. Barnard-Kelly, T. Battelino, F. Brosius, A. Ceriello +22 more
2025Cardiovascular Diabetology13 citations Open access
Semantic Scholar
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
O. Schnell, T. Battelino, R. Bergenstal, A. L. Birkenfeld +32 more
2023Cardiovascular Diabetology12 citations Open access
Semantic Scholar
Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short‐acting GLP‐1 analogue versus progression to basal‐bolus therapy
I. Hirsch, J. Buse, John Jack Leahy, J. McGill +6 more
2014Diabetes, obesity and metabolism11 citations
Semantic Scholar
The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus
F. Giorgino, T. Battelino, R. Bergenstal, T. Forst +5 more
2023Journal of Diabetes Science and Technology10 citations Open access
Semantic Scholar
54-OR: Oral Semaglutide vs. Empagliflozin Added On to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2
E. Montanya, J. Rosenstock, L. Canani, C. Deerochanawong +6 more
2019Diabetes10 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Buse×7
Invite
J. Buse — researcher profile on SciRah
F. Giorgino×7
Invite
F. Giorgino — researcher profile on SciRah
B. Bode×6
Invite
B. Bode — researcher profile on SciRah
A. Ceriello×6
Invite
A. Ceriello — researcher profile on SciRah

×5

Invite

T. Battelino — researcher profile on SciRah

Invite

S. Gough — researcher profile on SciRah

T. Vilsbøll×5

Invite

T. Vilsbøll — researcher profile on SciRah

Invite

J. Pettus — researcher profile on SciRah

Invite

V. Woo — researcher profile on SciRah

Invite

S. Linjawi — researcher profile on SciRah

Y. Handelsman×4

Invite

Y. Handelsman — researcher profile on SciRah

Oliver Schnell×4

Invite

Oliver Schnell — researcher profile on SciRah